Alector's AL002 misses primary endpoint in Alzheimer's trial. BofA downgrades stock, cuts price target, and highlights near-term challenges.
Alector’s AbbVie-partnered Alzheimer's disease asset has failed to slow disease progression in a phase 2 study, the latest in ...
As previously reported, BofA downgraded Alector (ALEC) to Underperform from Neutral with a price target of $1, down from $9, after ALOO2 missed ...
BofA downgraded Alector (ALEC) to Underperform from Neutral with a price target of $1, down from $9.Don't Miss our Black Friday Offers:Unlock ...
The brain drug developer is letting go of around 41 of its 238 employees, in a move the company says will help “align ...
Alector is kicking off a resource realignment effort that will include a workforce reduction of around 17%. The biotech ...
Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering novel, genetically validated therapies for ...
GlobalData on MSN8d
Alector stock drops after Alzheimer’s drug fails in Phase II trial"Alector stock drops after Alzheimer’s drug fails in Phase II trial" was originally created and published by Clinical Trials ...
Alector Therapeutics, working with AbbVie, was testing whether modulating immune cells in brain would slow Alzheimer's ...
Vigil Neuroscience's stock dropped after Alector's AL002 failed in Alzheimer's, raising concerns about VG-3927's efficacy.
On Friday, Alector Inc (ALEC) stock saw a modest uptick, ending the day at $2.6 which represents a slight increase of $0.05 or 1.96% from the prior close of $2.55. The stock opened at $2.55 and ...
Alector has significant cash reserves but faces high cash burn, with no immediate catalysts and uncertain prospects for its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback